BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 20939024)

  • 1. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells.
    Schulze J; Bickert T; Beil FT; Zaiss MM; Albers J; Wintges K; Streichert T; Klaetschke K; Keller J; Hissnauer TN; Spiro AS; Gessner A; Schett G; Amling M; McKenzie AN; Horst AK; Schinke T
    J Bone Miner Res; 2011 Apr; 26(4):704-17. PubMed ID: 20939024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substance P stimulates bone marrow stromal cell osteogenic activity, osteoclast differentiation, and resorption activity in vitro.
    Wang L; Zhao R; Shi X; Wei T; Halloran BP; Clark DJ; Jacobs CR; Kingery WS
    Bone; 2009 Aug; 45(2):309-20. PubMed ID: 19379851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
    Nagata N; Kitaura H; Yoshida N; Nakayama K
    Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
    Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
    J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. M-CSF priming of osteoclast precursors can cause osteoclastogenesis-insensitivity, which can be prevented and overcome on bone.
    De Vries TJ; Schoenmaker T; Aerts D; Grevers LC; Souza PP; Nazmi K; van de Wiel M; Ylstra B; Lent PL; Leenen PJ; Everts V
    J Cell Physiol; 2015 Jan; 230(1):210-25. PubMed ID: 24962140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
    Sankar U; Patel K; Rosol TJ; Ostrowski MC
    J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro.
    Balani D; Aeberli D; Hofstetter W; Seitz M
    Arthritis Rheum; 2013 Feb; 65(2):436-46. PubMed ID: 23124514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis.
    Lee SK; Kalinowski JF; Jastrzebski SL; Puddington L; Lorenzo JA
    Endocrinology; 2003 Aug; 144(8):3524-31. PubMed ID: 12865334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
    Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis.
    Miyauchi Y; Ninomiya K; Miyamoto H; Sakamoto A; Iwasaki R; Hoshi H; Miyamoto K; Hao W; Yoshida S; Morioka H; Chiba K; Kato S; Tokuhisa T; Saitou M; Toyama Y; Suda T; Miyamoto T
    J Exp Med; 2010 Apr; 207(4):751-62. PubMed ID: 20368579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss.
    Zaiss MM; Kurowska-Stolarska M; Böhm C; Gary R; Scholtysek C; Stolarski B; Reilly J; Kerr S; Millar NL; Kamradt T; McInnes IB; Fallon PG; David JP; Liew FY; Schett G
    J Immunol; 2011 Jun; 186(11):6097-105. PubMed ID: 21515798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-4 directly inhibits tumor necrosis factor-alpha-mediated osteoclast formation in mouse bone marrow macrophages.
    Kitaura H; Nagata N; Fujimura Y; Hotokezaka H; Tatamiya M; Nakao N; Yoshida N; Nakayama K
    Immunol Lett; 2003 Sep; 88(3):193-8. PubMed ID: 12941478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
    Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
    Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis.
    Hofkens W; Grevers LC; Walgreen B; de Vries TJ; Leenen PJ; Everts V; Storm G; van den Berg WB; van Lent PL
    J Control Release; 2011 Jun; 152(3):363-9. PubMed ID: 21396411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
    Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
    J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoralen and Bakuchiol Ameliorate M-CSF Plus RANKL-Induced Osteoclast Differentiation and Bone Resorption Via Inhibition of AKT and AP-1 Pathways in Vitro.
    Chai L; Zhou K; Wang S; Zhang H; Fan N; Li J; Tan X; Hu L; Fan X
    Cell Physiol Biochem; 2018; 48(5):2123-2133. PubMed ID: 30110702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
    Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
    Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.